866-997-4948(US-Canada Toll Free)

Chronic Myelogenous Leukemia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2026

Published By :

Transparency Market Research

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 170 Pages

Global Chronic Myelogenous Leukemia Treatment Market: Overview

Chronic Myelogenous Leukemia (CML) takes place when the bone marrow starts making too many white blood cells. This may affect red blood cells, white blood cells, and platelets. The first line treatment for CML in chronic phase is being largely treated with targeted drugs such as tyrosine kinase inhibitors (TKIs) nilotinib (Tasigna) and dasatinib (Sprycel). Meanwhile, in the initial phase drugs known as tyrosine kinase inhibitors (TKIs) are generally successful in controlling cancer.

Researchers are also trying to develop new strategies in order to test and identify new drugs efficiently and quickly. Researchers also believe that developing drugs that can act on multiple targets can be more effective in treating cancers with a network of alterations. It has also been found that combining drugs with treatments such as interferon, chemotherapy, and cancer vaccines can be more effective. Meanwhile, the University of Glasgow has also found that when antibiotic tigecycline combined with imatinib drug can eradicate leukemic stem cells and help in enhancing cure rate. More such research is being carried on to find better treatment for chronic myelogenous leukemia.

Global Chronic Myelogenous Leukemia Treatment Market: Research Methodology

The report provides an in-depth insight on some important aspects of the chronic myelogenous leukemia treatment global market and offers key insights on the growth patterns and factors resulting in the market growth, important segments, and competitive landscape.

The report provides both qualitative and quantitative analysis of the overall chronic myelogenous leukemia treatment market. The report also provides information on various factors shaping the market dynamics such as trends, opportunities, drivers, and restraints. The report also offers market attractiveness analysis, along with Porter’s five force analysis and SWOT analysis. Along with these, analysis on the market opportunity for the treatment type, drug type, distribution channel, and key developments has also been provided.

Key developments including the events occurred in past and events that are expected to take place during the forecast period from 2017 to 2026 has been offered in the report.  These industry developments are also likely to affect the market dynamics.

Global Chronic Myelogenous Leukemia Treatment Market: Market Segmentation

The global chronic myelogenous leukemia treatment market has been segmented into type of treatment, distribution channel, drug type and region. On the basis of treatment type, the segment includes disease specific treatment and symptomatic treatment. On the basis of drug type, the segment includes branded, and generic. On the basis of the distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, and retail pharmacies.

Geographically, the global chronic myelogenous leukemia treatment market is segmented into North America, Europe, Latin America, Asia Pacific Excluding Japan (APEJ), Japan, and the Middle East and Africa (MEA). The report segmentation includes country-wise analysis on the major parameters of the market. The forecast for each region, drug type, treatment type and distribution channel has been provided for the year 2017-2026. The CAGR in form of percentage and revenue share for each segment is included in the report.

Global Chronic Myelogenous Leukemia Treatment Market: Competition Landscape

The report offers a detailed profile on various leading market players in the global chronic myelogenous leukemia treatment market such as Bristol Myers Squibb, Novartis, Pfizer, Teva Pharmaceutical, Hoffman-LaRoche and Schering Plough, and Others. The evaluation of these leading market players has been done on various parameters including company overview, product portfolio, financial overview, business strategies, and new developments. The companies are investing in the research and development of new treatments and drugs to treat chronic myelogenous leukemia.

Chapter 1 Global Outlook

Chapter 2 Global Chronic Myelogenous Leukemia Treatment Market - Executive Summary

Chapter 3 Global Chronic Myelogenous Leukemia Treatment Market Overview
3.1 Introduction
      3.1.1 Global Chronic Myelogenous Leukemia Treatment Market Taxonomy
      3.1.2 Global Chronic Myelogenous Leukemia Treatment Market Definition
3.2 Global Chronic Myelogenous Leukemia Treatment Market Size (US$ Mn) and Forecast, 2012-2026
      3.2.1 Global Chronic Myelogenous Leukemia Treatment Market Y-o-Y Growth
3.3 Global Chronic Myelogenous Leukemia Treatment Market Dynamics
3.4 Supply Chain
3.5 Cost Structure
3.6 Pricing Analysis
      3.6.1 Pricing for Tablets
      3.6.2 Pricing for Injectable
3.7 Patent Analysis
3.8 Drug Regulations
3.9 List of Distributors
3.10 PESTL Analysis
3.11 Product Lifecycle
3.12 Key Participants Market Presence (Intensity Map) By Region

Chapter 4 Global Chronic Myelogenous Leukemia Treatment Market Analysis and Forecast 2012-2026
4.1 Global Chronic Myelogenous Leukemia Treatment Market Size and Forecast by Treatment Type, 2012-2026
      4.1.1 Disease Specific Treatment Market Size and Forecast, 2012-2026
              4.1.1.1 Revenue (US$ Mn) Comparison, By Region
              4.1.1.2 Market Share Comparison, By Region
              4.1.1.3 Y-o-Y growth Comparison, By Region
      4.1.2 Symptomatic Treatment Market Size and Forecast, 2012-2026
              4.1.2.1 Revenue (US$ Mn) Comparison, By Region
              4.1.2.2 Market Share Comparison, By Region
              4.1.2.3 Y-o-Y growth Comparison, By Region
4.2 Global Chronic Myelogenous Leukemia Treatment Market Size and Forecast by Distribution Channel, 2012-2026
      4.2.1 Hospital Pharmacies Market Size and Forecast, 2012-2026
              4.2.1.1 Revenue (US$ Mn) Comparison, By Region
              4.2.1.2 Market Share Comparison, By Region
              4.2.1.3 Y-o-Y growth Comparison, By Region
      4.2.2 Specialty Pharmacies Market Size and Forecast, 2012-2026
              4.2.2.1 Revenue (US$ Mn) Comparison, By Region
              4.2.2.2 Market Share Comparison, By Region
              4.2.2.3 Y-o-Y growth Comparison, By Region
      4.2.3 Retail Pharmacies Market Size and Forecast, 2012-2026
              4.2.3.1 Revenue (US$ Mn) Comparison, By Region
              4.2.3.2 Market Share Comparison, By Region
              4.2.3.3 Y-o-Y growth Comparison, By Region
4.3 Global Chronic Myelogenous Leukemia Treatment Market Size and Forecast by Drug Type, 2012-2026
      4.3.1 Branded Market Size and Forecast, 2012-2026
              4.3.1.1 Revenue (US$ Mn) Comparison, By Region
              4.3.1.2 Market Share Comparison, By Region
              4.3.1.3 Y-o-Y growth Comparison, By Region
      4.3.2 Generic Market Size and Forecast, 2012-2026
              4.3.2.1 Revenue (US$ Mn) Comparison, By Region
              4.3.2.2 Market Share Comparison, By Region
              4.3.2.3 Y-o-Y growth Comparison, By Region

Chapter 5 North America Chronic Myelogenous Leukemia Treatment Market Size and Forecast, 2012-2026
5.1 Regional Outlook
      5.1.1 Political Outlook
      5.1.2 Economic Outlook
      5.1.3 Business Environment Outlook
      5.1.4 North America Healthcare Sector Outlook
      5.1.5 Chronic Myelogenous Leukemia Treatment – North America Region Outlook
5.2 Revenue (US$ Mn) Comparison, By Country
5.3 Revenue (US$ Mn) Comparison, By Treatment Type
5.4 Revenue (US$ Mn) Comparison, By Distribution Channel
5.5 Revenue (US$ Mn) Comparison, By Drug Type

Chapter 6 Latin America Chronic Myelogenous Leukemia Treatment Market Size and Forecast, 2012-2026
6.1 Regional Outlook
      6.1.1 Political Outlook
      6.1.2 Economic Outlook
      6.1.3 Business Environment Outlook
      6.1.4 Latin America Healthcare Sector Outlook
      6.1.5 Chronic Myelogenous Leukemia Treatment – Latin America Region Outlook
6.2 Revenue (US$ Mn) Comparison, By Country
6.3 Revenue (US$ Mn) Comparison, By Treatment Type
6.4 Revenue (US$ Mn) Comparison, By Distribution Channel
6.5 Revenue (US$ Mn) Comparison, By Drug Type

Chapter 7 Europe Chronic Myelogenous Leukemia Treatment Market Size and Forecast, 2012-2026
7.1 Regional Outlook
      7.1.1 Political Outlook
      7.1.2 Economic Outlook
      7.1.3 Business Environment Outlook
      7.1.4 Europe Healthcare Sector Outlook
      7.1.5 Chronic Myelogenous Leukemia Treatment – Europe Region Outlook
7.2 Revenue (US$ Mn) Comparison, By Country
7.3 Revenue (US$ Mn) Comparison, By Treatment Type
7.4 Revenue (US$ Mn) Comparison, By Distribution Channel
7.5 Revenue (US$ Mn) Comparison, By Drug Type

Chapter 8 Japan Chronic Myelogenous Leukemia Treatment Market Size and Forecast, 2012-2026
8.1 Regional Outlook
      8.1.1 Political Outlook
      8.1.2 Economic Outlook
      8.1.3 Business Environment Outlook
      8.1.4 Japan Healthcare Sector Outlook
      8.1.5 Chronic Myelogenous Leukemia Treatment – Japan Region Outlook
8.2 Revenue (US$ Mn) Comparison, By Country
8.3 Revenue (US$ Mn) Comparison, By Treatment Type
8.4 Revenue (US$ Mn) Comparison, By Distribution Channel
8.5 Revenue (US$ Mn) Comparison, By Drug Type

Chapter 9 APEJ Chronic Myelogenous Leukemia Treatment Market Size and Forecast, 2012-2026
9.1 Regional Outlook
      9.1.1 Political Outlook
      9.1.2 Economic Outlook
      9.1.3 Business Environment Outlook
      9.1.4 Asia Pacific Excluding Japan (APEJ) Healthcare Sector Outlook
      9.1.5 Chronic Myelogenous Leukemia Treatment – APEJ Region Outlook
9.2 Revenue (US$ Mn) Comparison, By Country
9.3 Revenue (US$ Mn) Comparison, By Treatment Type
9.4 Revenue (US$ Mn) Comparison, By Distribution Channel
9.5 Revenue (US$ Mn) Comparison, By Drug Type

Chapter 10 MEA Chronic Myelogenous Leukemia Treatment Market Size and Forecast, 2012-2026
10.1 Regional Outlook
      10.1.1 Political Outlook
      10.1.2 Economic Outlook
      10.1.3 Business Environment Outlook
      10.1.4 Middle East & Africa (MEA) Healthcare Sector Outlook
      10.1.5 Chronic Myelogenous Leukemia Treatment – MEA Region Outlook
10.2 Revenue (US$ Mn) Comparison, By Country
10.3 Revenue (US$ Mn) Comparison, By Treatment Type
10.4 Revenue (US$ Mn) Comparison, By Distribution Channel
10.5 Revenue (US$ Mn) Comparison, By Drug Type

Chapter 11 Global Chronic Myelogenous Leukemia Treatment Market Competitive Landscape and Company Profile
11.1 Global Chronic Myelogenous Leukemia Treatment Market: Company Share Analysis
11.2 Global Chronic Myelogenous Leukemia Treatment Market: Company Dashboard
11.3 Global Chronic Myelogenous Leukemia Treatment Market: Company Profiles
      11.3.1 Bristol-Myers Squibb Company
              11.3.1.1 Company Overview
              11.3.1.2 Product Overview
              11.3.1.3 Key Financials
              11.3.1.4 Key Developments
              11.3.1.5 SWOT Analysis
      11.3.2 Novartis AG
              11.3.2.1 Company Overview
              11.3.2.2 Product Overview
              11.3.2.3 Key Financials
              11.3.2.4 SWOT Analysis
      11.3.3 Pfizer Inc.
              11.3.3.1 Company Overview
              11.3.3.2 Product Overview
              11.3.3.3 Key Financials
              11.3.3.4 Key Developments
              11.3.3.5 SWOT Analysis
      11.3.4 Teva Pharmaceuticals
              11.3.4.1 Company Overview
              11.3.4.2 Product Overview
              11.3.4.3 Key Financials
              11.3.4.4 Key Developments
              11.3.4.5 SWOT Analysis
      11.3.5 Roche Holdings AG
              11.3.5.1 Company Overview
              11.3.5.2 Product Overview
              11.3.5.3 Key Financials
              11.3.5.4 Key Developments
              11.3.5.5 SWOT Analysis
      11.3.6 Incyte Corporation
              11.3.6.1 Company Overview
              11.3.6.2 Product Overview
              11.3.6.3 Key Developments
      11.3.7 Bio-Path Holdings, Inc.
              11.3.7.1 Company Overview
              11.3.7.2 Product Overview

Chapter 12 TMR Research Methodology

Chapter 13 Disclaimer and Contact information

List of Table

List of Tables

TABLE 1 Global Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), 2012-2017
TABLE 2 Global Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), 2018-2026
TABLE 3 Global Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn) and Y-o-Y, 2017-2026
TABLE 4 Global Disease Specific Treatment Segment Value (US$ Mn), By Region 2012-2017
TABLE 5 Global Disease Specific Treatment Segment Value (US$ Mn), By Region 2018-2026
TABLE 6 Global Disease Specific Treatment Segment Market Share, By Region 2012-2017
TABLE 7 Global Disease Specific Treatment Segment Market Share, By Region 2018-2026
TABLE 8 Global Disease Specific Treatment Segment Y-o-Y, By Region 2017-2026
TABLE 9 Global Symptomatic Treatment Segment Value (US$ Mn), By Region 2012-2017
TABLE 10 Global Symptomatic Treatment Segment Value (US$ Mn), By Region 2018-2026
TABLE 11 Global Symptomatic Treatment Segment Market Share, By Region 2012-2017
TABLE 12 Global Symptomatic Treatment Segment Market Share, By Region 2018-2026
TABLE 13 Global Symptomatic Treatment Segment Y-o-Y, By Region 2017-2026
TABLE 14 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 15 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 16 Global Hospital Pharmacies Segment Market Share, By Region 2012-2017
TABLE 17 Global Hospital Pharmacies Segment Market Share, By Region 2018-2026
TABLE 18 Global Hospital Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 19 Global Specialty Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 20 Global Specialty Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 21 Global Specialty Pharmacies Segment Market Share, By Region 2012-2017
TABLE 22 Global Specialty Pharmacies Segment Market Share, By Region 2018-2026
TABLE 23 Global Specialty Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 24 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2012-2017
TABLE 25 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2018-2026
TABLE 26 Global Retail Pharmacies Segment Market Share, By Region 2012-2017
TABLE 27 Global Retail Pharmacies Segment Market Share, By Region 2018-2026
TABLE 28 Global Retail Pharmacies Segment Y-o-Y, By Region 2017-2026
TABLE 29 Global Branded Segment Value (US$ Mn), By Region 2012-2017
TABLE 30 Global Branded Segment Value (US$ Mn), By Region 2018-2026
TABLE 31 Global Branded Segment Market Share, By Region 2012-2017
TABLE 32 Global Branded Segment Market Share, By Region 2018-2026
TABLE 33 Global Branded Segment Y-o-Y, By Region 2017-2026
TABLE 34 Global Generic Segment Value (US$ Mn), By Region 2012-2017
TABLE 35 Global Generic Segment Value (US$ Mn), By Region 2018-2026
TABLE 36 Global Generic Segment Market Share, By Region 2012-2017
TABLE 37 Global Generic Segment Market Share, By Region 2018-2026
TABLE 38 Global Generic Segment Y-o-Y, By Region 2017-2026
TABLE 39 North America Current Expenditure on Health, (% of GDP), by Country, 2010 – 2016
TABLE 40 North America Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016
TABLE 41 North America Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016
TABLE 42 North America Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016
TABLE 43 North America Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016
TABLE 44 North America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2012-2017
TABLE 45 North America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2018-2026
TABLE 46 North America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2012-2017
TABLE 47 North America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2018-2026
TABLE 48 North America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 49 North America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 50 North America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 51 North America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 52 Latin America Current Expenditure on Health, (% of GDP), by Country, 2010 – 2016
TABLE 53 Latin America Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016
TABLE 54 Latin America Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016
TABLE 55 Latin America Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016
TABLE 56 Latin America Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016
TABLE 57 Latin America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2012-2017
TABLE 58 Latin America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2018-2026
TABLE 59 Latin America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2012-2017
TABLE 60 Latin America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2018-2026
TABLE 61 Latin America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 62 Latin America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 63 Latin America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 64 Latin America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 65 Europe Current Expenditure on Health, (% of GDP), by Country, 2010 – 2016
TABLE 66 Europe Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016
TABLE 67 Europe Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016
TABLE 68 Europe Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016
TABLE 69 Europe Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016
TABLE 70 Europe Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2012-2017
TABLE 71 Europe Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2018-2026
TABLE 72 Europe Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2012-2017
TABLE 73 Europe Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2018-2026
TABLE 74 Europe Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 75 Europe Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 76 Europe Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 77 Europe Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 78 Japan Current Expenditure on Health, (% of GDP), by Country, 2010 – 2016
TABLE 79 Japan Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016
TABLE 80 Japan Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016
TABLE 81 Japan Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016
TABLE 82 Japan Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016
TABLE 83 Japan Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2012-2017
TABLE 84 Japan Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2018-2026
TABLE 85 Japan Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2012-2017
TABLE 86 Japan Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2018-2026
TABLE 87 Japan Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 88 Japan Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 89 Japan Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 90 Japan Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 91 APEJ Current Expenditure on Health, (% of GDP), by Country, 2010 – 2016
TABLE 92 APEJ Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016
TABLE 93 APEJ Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016
TABLE 94 APEJ Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016
TABLE 95 APEJ Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016
TABLE 96 APEJ Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2012-2017
TABLE 97 APEJ Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2018-2026
TABLE 98 APEJ Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2012-2017
TABLE 99 APEJ Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2018-2026
TABLE 100 APEJ Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 101 APEJ Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 102 APEJ Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 103 APEJ Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2018-2026
TABLE 104 MEA Current Expenditure on Health, (% of GDP), by Country, 2010 – 2016
TABLE 105 MEA Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016
TABLE 106 MEA Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016
TABLE 107 MEA Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016
TABLE 108 MEA Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016
TABLE 109 MEA Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2012-2017
TABLE 110 MEA Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2018-2026
TABLE 111 MEA Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2012-2017
TABLE 112 MEA Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2018-2026
TABLE 113 MEA Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
TABLE 114 MEA Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
TABLE 115 MEA Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2012-2017
TABLE 116 MEA Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2018-2026

List of Chart

List of Figures

FIG. 1 Global Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), 2012-2017
FIG. 2 Global Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn) Forecast, 2018-2026
FIG. 3 Global Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn) and Y-o-Y, 2017-2026
FIG. 4 Global Disease Specific Treatment Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 5 Global Disease Specific Treatment Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 6 Global Disease Specific Treatment Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 7 Global Symptomatic Treatment Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 8 Global Symptomatic Treatment Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 9 Global Symptomatic Treatment Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 10 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 11 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 12 Global Hospital Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 13 Global Specialty Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 14 Global Specialty Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 15 Global Specialty Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 16 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 17 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 18 Global Retail Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 19 Global Branded Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 20 Global Branded Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 21 Global Branded Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 22 Global Generic Segment Market Value (US$ Mn) By Region, 2012-2017
FIG. 23 Global Generic Segment Market Value (US$ Mn) By Region, 2018-2026
FIG. 24 Global Generic Segment Y-o-Y Growth Rate, By Region, 2017-2026
FIG. 25 North America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2012-2017
FIG. 26 North America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2018-2026
FIG. 27 North America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2012-2017
FIG. 28 North America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2018-2026
FIG. 29 North America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 30 North America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 31 North America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2012-2017
FIG. 32 North America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2018-2026
FIG. 33 Latin America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2012-2017
FIG. 34 Latin America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2018-2026
FIG. 35 Latin America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2012-2017
FIG. 36 Latin America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2018-2026
FIG. 37 Latin America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 38 Latin America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 39 Latin America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2012-2017
FIG. 40 Latin America Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2018-2026
FIG. 41 Europe Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2012-2017
FIG. 42 Europe Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2018-2026
FIG. 43 Europe Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2012-2017
FIG. 44 Europe Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2018-2026
FIG. 45 Europe Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 46 Europe Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 47 Europe Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2012-2017
FIG. 48 Europe Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2018-2026
FIG. 49 Japan Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2012-2017
FIG. 50 Japan Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2018-2026
FIG. 51 Japan Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2012-2017
FIG. 52 Japan Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2018-2026
FIG. 53 Japan Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2012-2017
FIG. 54 Japan Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 55 Japan Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2012-2017
FIG. 56 Japan Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2018-2026
FIG. 57 APEJ Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2012-2017
FIG. 58 APEJ Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2018-2026
FIG. 59 APEJ Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2012-2017
FIG. 60 APEJ Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2018-2026
FIG. 61 APEJ Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 62 APEJ Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 63 APEJ Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2012-2017
FIG. 64 APEJ Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2018-2026
FIG. 65 MEA Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2012-2017
FIG. 66 MEA Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Country 2018-2026
FIG. 67 MEA Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2012-2017
FIG. 68 MEA Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Treatment Type 2018-2026
FIG. 69 MEA Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2012-2017
FIG. 70 MEA Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Distribution Channel 2018-2026
FIG. 71 MEA Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2012-2017
FIG. 72 MEA Chronic Myelogenous Leukemia Treatment Market Value (US$ Mn), By Drug Type 2018-2026

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *